We hypothesized that a whey protein diet would result in greater weight loss and improved body composition compared with standard weight loss diets. Weight change, body composition, and renin-angiotensin aldosterone system activity in midlife adults were compared between diet groups. Eighteen subjects enrolled in a 5-month study of 8-week controlled food intake followed by 12-weeks ad libitum intake. Subjects were randomized to 1 of 3 treatment groups: control diet (CD) (55% carbohydrate/15% protein/30% fat), mixed protein (40% carbohydrate/30% protein/30% fat), or whey protein (WP) (40% carbohydrate/15% mixed protein/15% whey protein/30% fat). Measurements included weight, metabolic measures, body composition by dual-energy x-ray absorptiometry, and resting energy expenditure. No statistically significant differences in total weight loss or total fat loss were observed between treatments; however, a trend toward greater total weight loss (P = .08) and total fat loss (P = .09) was observed in the WP group compared with the CD group. Fat loss in the leg and gynoid regions was greater (P b .05) in the WP group than the CD group. No renin-angiotensin aldosterone system-mediated response was observed, but a decrease in systolic blood pressure was significantly greater (P b .05) in the WP group compared with the CD group. In summary, increased whey protein intake did not result in statistically significant differences in weight loss or in total fat loss, but significant differences in regional fat loss and in decreased blood pressure were observed in the WP group.
Introduction
In the United States, there is a greater likelihood of obesity among men and women 40 to 59 years of age compared with men and women 20 to 39 years [1] . Obesity in midlife is associated with higher risk of metabolic disease [2, 3] . Energy restriction diets of various compositions have been proposed to control weight gain and promote weight loss. Multiple studies have reported successful weight loss and maintenance of lean mass using energy-restricted diets of moderate-to high-protein content (≥25% energy from protein) [4] [5] [6] . Generally, these diets have increased protein intake from meat, eggs, dairy, and nuts and decreased the proportion of energy from carbohydrates and fats.
In a single-meal study of macronutrient intake, protein decreased postprandial appetite and subsequent energy intake compared with either carbohydrate or fat [7] . Ad libitum intake of high-protein diets enhanced weight loss compared with diets with high-carbohydrate content [8, 9] . In a long-term study, subjects following a moderate protein diet were more successful in maintaining significant weight loss and improved body composition after 12 months compared with subjects following an average protein diet plan [10] .
Benefits associated with high-protein reduced energy diets include enhanced satiety [11] , increased thermogenesis [8] , and improved insulin sensitivity [12, 13] . These effects are thought to be associated with the branch chain amino acids (BCAA) found in complete proteins [13, 14] . In addition, the BCAA leucine signals intracellular pathways regulating amino acid oxidation and gluconeogenesis [15] . Whey protein (100 g) contains about 24 g of BCAA [16] , which have been associated with improved insulin sensitivity and satiety [17] . Some studies have investigated the use of whey protein in an ad libitum high-protein weight loss diet [18, 19] , but to our knowledge, whey protein has not been compared against other protein sources in a weight loss protocol.
Ideal weight loss results in reduction of fat mass with minimal loss of lean tissue; therefore, a better understanding of the mechanisms governing adipose activity is required. Recently, adipose metabolism has been found to be influenced by hormones previously identified in blood pressure homeostasis as the renin-angiotensin aldosterone system (RAAS) [20, 21] . With weight loss, decreases in renin, angiotensinogen, angiotensin-converting enzyme (ACE), and aldosterone have been observed [22] . In a study of the pharmaceutical ACE inhibitors enalapril and captopril, a slight loss of body weight was noted in the treatment groups [23] [24] [25] , although the metabolic pathway is still unclear. Whether the decrease in RAAS activity is an effect of weight loss or if the inhibition of the RAAS pathway also results in a loss of weight has not been specifically tested.
Recent studies have proposed that the RAAS system can be inhibited with bioactive peptides found in food sources. Angiotensin-converting enzyme inhibition by small peptide groups found in whey protein has been observed in vitro [26] . There have been mixed results in human clinical studies, with some studies reporting an average decrease in systolic blood pressure of 7.0 mm Hg [27] [28] [29] and another study showing no significant difference in blood pressure [30] . The specific mechanism of action of whey peptides has not been determined. However, it is believed to involve direct inhibition of ACE by binding with the zinc fingers of the molecule resulting in the inability of ACE to cleave angiotensin I into angiotensin II [31] . It is not clear whether a decrease in blood pressure after consuming whey protein is directly related to ACE inhibition or some other mechanism.
Whey protein may be a preferred protein choice for a weight loss diet because of its high BCAA content, the potential bioactivity with the RAAS of adipose tissue, the potential to increase satiety, and its ease of incorporation into a diet plan. We hypothesized that a whey protein diet (WP) would result in greater weight loss and improved body composition compared with standard weight loss diets. Using a randomized, parallel design of 3 diets, our objectives were to determine weight loss, body composition, insulin sensitivity, satiety, blood pressure, and RAAS activity in midlife adults who were following an energy-restricted protocol to promote weight loss. Based on the literature, increased consumption of whey protein may decrease ACE activity and may be related to maintenance of lean mass. Measures of changes in ACE activity, plasma renin activity, and aldosterone concentration were compared with changes in body composition for each diet group.
Methods and materials

Study design
A randomized, parallel design was used to compare the effects of diets containing varying protein quantities from different protein sources. After signing consent forms, subjects were randomized to a control diet (CD), mixed protein diet (MP), or WP (Fig. 1 ). Subjects were directed to maintain their daily activity habits and not increase physical activity during the study.
For the first 8 weeks, all the food to be consumed was provided to the subjects. Subjects came daily to the General Clinical Research Center (GCRC) of the University of Minnesota to pick up meals. At daily visits, each subject Fig. 1 . Flow diagram for the study design and subjects. completed a compliance questionnaire and a satiety questionnaire and was weighed.
On completion of the 8-week feeding phase, subjects continued on their assigned diet for an additional 12-week ad libitum phase. Subjects were instructed by a registered dietitian on how to continue the assigned diet. Those subjects assigned to WP were given additional Designer Whey protein powder and Pure Protein bars. Subjects were expected to report daily intake on a secure, personal dietary analysis Web program (www.nutrihand.com), which the principal investigator could evaluate for compliance. Every 4 weeks, each subject returned to the GCRC to be weighed and have blood drawn for fasting glucose and insulin levels. At baseline and 8 and 20 weeks, each subject came to the GCRC for evaluations, including indirect calorimetry to measure resting energy expenditure (REE), fasting glucose and insulin, RAAS activity, and a dual-energy x-ray absorptiometry (DXA) scan to measure body composition. Concentrations of fasting glucose and insulin were used to calculate the homeostatic model assessment of insulin resistance (HOMA-IR; =[fasting glucose (mmol/L) ⁎ fasting insulin (μU/mL)]/22.5) [32] at these 3 clinical visits.
Approval of the study was obtained from the University of Minnesota Committee for the Use of Human Subjects and Research. The entire study was performed at the University of Minnesota GCRC.
Subjects
Healthy, midlife (40-60 years) adults were recruited from the Minneapolis-St Paul metropolitan area through local posters and advertisement. Eligibility was determined by responses to a telephone interview, and subjects were disqualified if they reported a current medical problem, were pregnant, or were using prescription medication. Subjects were asked about their willingness to comply with dietary treatments. Inclusion criteria included the following: a body mass index (BMI) of 27 to 32 kg/m 2 , no recent weight changes, a fasting blood glucose measure less than 126 mg/ dL, and a desire to lose weight. Of 85 individuals screened by telephone interview, 27 were eligible for further screening at the GCRC. A total of 18 participants consented to the protocol and were enrolled in the study.
Resting energy expenditure
At the screening visit, eligible subjects had their REE measured with the ParvoMedics True One Metabolic Monitor (Provo, Utah). All REE measures were completed in a fasting state after the subject had rested in a supine position for about 30 minutes. Fifteen minutes of a stable, continuous measure were used to calculate the baseline REE for each subject [33] . The baseline REE was evaluated along with the activity level reported by each subject to determine total energy needs. To determine the activity level, each subject was asked if they regularly engaged in specific activities and what duration of time was spent in each given activity. From this evaluation, a custom-reduced energy diet was tailored to promote 0.75-kg weight loss weekly. Each subject's usual food consumption before starting the study was assessed by the Diet History Questionnaire (NCI, 2003).
Dietary treatments
The macronutrient composition for each dietary treatment is shown in Table 1 . All 3 diets were similar in dietary fiber, cholesterol, calcium intake, and fatty acid balance. Ad libitum additions of salt were not controlled with these diets. Diets were designed to differ in the percentage of energy from protein and the protein source. The 2 high-protein diets contained 30% energy from protein and 40% energy from carbohydrate compared with CD, which contained 15% energy from protein and 55% energy from carbohydrate. The CD and the MP diets contained protein from the same sources, but in different quantities. The WP diet contained the same quantity of protein by mass as the MP, but the entire increase of protein above the level of the CD came from the addition of Designer Whey, a commercial whey protein isolate. Daily calcium intake was balanced across groups by providing supplemental calcium tablets (Caltrate 600) to subjects in the CD and MP groups.
Experimental diets were formulated with commonly available food items, including whey protein, as shown in Table 2 . A 5-day menu rotation was developed and then modified for each experimental group. The nutrient composition of the test diets was calculated with Nutritionist V nutrient analysis software (Hearst Corporation, 2005). The nutrient data for all food items used in the menus were obtained from the United States Department of Agriculture standard reference database as included in Nutritionist V.
Dietary compliance and satiety assessment
Subjects completed compliance questionnaires on a daily basis during the 8-week feeding phase. The first questionnaire asked the subject to report all quantities of provided food left uneaten and to specify any additional food that had been consumed during the previous 24 hours. In the second questionnaire, satiety was evaluated by use of a Labeled Affective Magnitude scale [34, 35] . Similar to a visual analog scale, this scale contained phrases describing different degrees of hunger or fullness on a 100-mm vertical line (0 mm, "Greatest Imaginable Hunger"; 50 mm, "Neither hungry nor full"; 100 mm, "Greatest Imaginable Fullness"). Subjects were instructed to mark the vertical line at the place that best described their current feeling of hunger or fullness. During the 12-week ad libitum phase, compliance was monitored by daily online recording via the Nutrihand.com Web site. The online records were reviewed weekly by investigators with feedback provided to each subject by e-mail. Records were evaluated for maintenance of restricted energy intake and assigned protein intake. The average weekly intake for each subject was calculated from the selection of consecutive days in each week with 3 or more meals recorded each day. The mean intake per treatment group was calculated using the average weekly intake of each subject.
Blood analyses
After fasting overnight, plasma samples were collected from subjects in EDTA vacutainer tubes for analysis of plasma renin concentrations. Serum samples were collected in vacutainer tubes for glucose, insulin, aldosterone, and ACE analysis. Samples were separated by centrifuge at 2000 × g and 5°C for 20 minutes and then individually labeled and stored at −80°C until analysis was completed.
Insulin was measured with a commercially available enzyme-linked immunosorbent assay kit (LINCO Research, St Charles, Mo) with a range of 2 to 200 μU/mL. The procedure used microtiter plates coated with an antibody for human insulin. Samples were added to the prescribed wells, and additional antibodies were added to sandwich the captured insulin. Quantification of the captured insulin was accomplished by measuring the activity of horseradish peroxidase in tetramethylbenzidine with an enzyme-linked immunosorbent assay reader. Glucose was measured with a spectrophotometric protocol developed by Morin and Prox [36] . A 2.5-mL glucose oxidase-peroxidase reagent was added in duplicate to 50 μL serum samples, vortexed, and then incubated 2 minutes before measuring absorbance in the spectrophotometer (Varian Cray 50 2.0; Agilent Technologies, Santa Clara, CA). Angiotensin-converting enzyme activity was measured with a commercially available spectrophotometric assay (ALPCO Immunoassays, Salem, NH) with a reference range of 27 to 68 U/L. The production of hippuric acid by ACE was stopped with the addition of HCl and the product then combined with cyanuric chloride to a measurable absorbance at 382 nm [37] . Plasma renin activity was measured with a commercially available immunoradiometric assay (Diagnostic Systems Laboratories, Webster, Tex) with lower and upper detection limits of 5 and 500 pg/mL, respectively. The assay measured the renin that was attached to 2 antibodies in a noncompetitive enzyme reaction [38] . Aldosterone was measured with a commercially available radioimmunoassay (Diagnostic Systems Laboratories) with lower and upper detection limits of 25 and 1600 pg/mL, respectively. This competitive radioimmunoassay measured the aldosterone bound to the antibody, which is inversely proportional to the aldosterone present in the original sample [39] .
Body composition measures
Body weight was measured on an electronic scale (ScaleTronix 5005 Stand-On Scale; Scale-Tronix, White Plains, NY) to the nearest ± 0.1 kg, with subjects wearing light clothing and no shoes. Height was measured to the nearest ± 1.0 cm on a stadiometer attached to the scale. Body mass index was calculated as kilograms per meter squared. Dualenergy x-ray absorptiometry measures of total body, lumbar spine, and dual femur were completed at baseline and at [40] . In addition to total body measures, the DXA software identified 5 regions for additional analysis: trunk, arm, leg, gynoid, and android regions. The android region is defined as the waist area starting from a longitudinal line directly above the pelvis and progressing upward a height that is 20% of the measured distance from the pelvis to the neck base. The gynoid region is defined from a longitudinal line at the top of the pelvis and progressing downward a total height twice as high as the android region [41] .
Statistical analyses
All data are presented as means (±SEM) of each dietary treatment group. The groups were compared using the analysis of variance in Procedure General Linear Models (Proc GLM) (SAS version 9.2; SAS Institute, Inc, Cary, NC). Area under the curve was measured for sodium and potassium intake during the ad libitum phase of the trial. The overall F test is reported, with the results of pairwise group comparisons and tests of within-group changes from baseline. Results were considered significant at P b .05.
Results
Subjects
Randomization of subjects to the 3 treatment groups was successful. At baseline, no statistically significant differences existed between treatment groups for age, weight, BMI, or percent body fat (Table 3 ). All subjects completed the 8-week feeding phase of the trial, and 1 female participant from each group did not complete the 12-week ad libitum phase (Fig. 1) . Follow-up with noncompleters indicated the reasons for not returning for follow-up clinical visits were life challenges and dissatisfaction with rate of weight loss.
Weight loss and body composition
Significant weight loss within each treatment group was observed (P b .05 for CD, MP, and WP, ranging from 6 to almost 10 kg). Differences in weight loss between all 3 treatments were not significant. However, there was a trend (P = .08) toward greater weight loss in the WP group compared with the CD group.
Body composition improved with a reduction in fat mass in all treatment groups. There was an observed trend of greater total fat mass loss (P = .09) in the WP group compared with the CD group, especially in the leg and gynoid regions (Fig. 2) . In addition, there were some regional differences in lean mass changes between treatments ( Fig. 3) with the WP group showing slightly greater loss of lean mass in association with greater total body weight reduction. In comparison by fat/lean ratio, the CD group showed a loss of 5.6:1 g compared with a loss of 8.4:1 g with the WP group. The difference in total lean mass loss between groups at week 20 was not significantly different. 
RAAS activity, blood pressure, and metabolic measures
Plasma renin and ACE activities and aldosterone concentration are reported in Table 4 . Renin activity was not significantly different between groups and did not change over the 5-month protocol. Angiotensin-converting enzyme activity in the CD group was higher at baseline compared with the other treatment groups, but the difference was not statistically significant. By week 8, all the groups had similar ACE measures with a significant decrease within the CD group (P b .05). Over the 20 weeks, ACE activity decreased in the WP group but was not statistically different from other groups. Aldosterone concentration was similar at baseline between treatments, and a trend toward decreasing aldosterone concentration (P = .08) was observed in the CD and WP groups at week 20.
Systolic blood pressure decreased in all 3 treatments during the first 8 weeks. At the conclusion of the study, there was a significant difference (P b .04) in change of systolic blood pressure between the CD and WP treatments. There were no significant changes in diastolic blood pressure between treatments.
No significant differences were observed between groups for fasting glucose or insulin measures at any time point in the study. The values of HOMA-IR at baseline were similar between groups, and the decreasing values observed with all treatments were not significantly different at week 8 or 20.
Dietary results
Protein intake between diets was significantly different throughout the 20 weeks. As designed, protein intake during the feeding phase for the CD group averaged 0.8 g kg −1 d −1 , whereas protein intake of the MP and WP groups averaged 1.4 g kg
A comparison of the essential amino acid composition average between the MP and WP treatment during the feeding phase showed an increase by mass in tryptophan (48%), threonine (63%), isoleucine (27%), leucine (45%), cystine (46%), and valine (21%) with daily intake in the WP treatment. This increase is based primarily on the additional whey protein consumed in the diet.
During the ad libitum phase, protein intake of the CD group increased to 1.1 g kg
, and protein intake of the MP group was 1.3 g kg −1 d −1 , whereas the WP group maintained 1.4 g kg
Subjects maintained a protein and carbohydrate intake that was significantly different (P b .05) between the CD treatment and both high-protein treatments. No significant difference in area under the curve analysis for sodium and potassium intake was observed. However, the self-reported online dietary records did not ask subjects to report added salt. Ninety-three percent of the subjects reported ad libitum intake for more than 6 weeks, and 53% of the subjects reported all weeks of ad libitum intake.
Satiety
Average satiety responses during the feeding phase showed that even on a reduced energy diet, most subjects reported "fullness" (N50 mm). Average weekly responses did not show a significant difference between the groups. However, the WP group reported the least variability during the entire 8 weeks as shown in Fig. 4 . By week 8, a trend (P = .08) toward differences between the WP and the other treatments was observed at the "Neither hungry nor full" level.
Discussion
In our study design, incorporating custom-reduced energy diets, all subjects showed similar weight loss and circulating hormone activity even though dietary composition was significantly different. Therefore, the hypothesis that WP would result in greater weight loss and improved body composition compared with standard weight loss diets was rejected in this study. Although the measured outcomes were not statistically different, there was a trend in the WP group toward greater weight loss, greater fat loss, and reduced blood pressure compared with the other treatment groups.
There was no evidence to support a RAAS-mediated effect as a possible mechanism to explain the blood pressure changes in the WP group. Some previous weight loss studies [42, 43] have reported decreases in plasma renin and ACE activities as well as aldosterone concentrations when subjects have achieved greater than 3% weight loss. It is important to note that all of our subjects achieved greater than 3% weight loss and showed no significant differences among the 3 diets in RAAS activity as assessed by renin and ACE activity and aldosterone level. Therefore, our results fail to identify a weight loss mechanism related to a decrease in circulating ACE activity and the consumption of whey protein at the levels provided (15% of energy). In a previous study, when a high-protein diet (2.0 g kg −1 d −1 ) was fed in a weight maintenance diet to normal-weight subjects, increased plasma renin activity and aldosterone were observed [44] . Two of our treatments were high-protein diets, which may have contributed to sustaining RAAS measures even during weight loss. However, the CD group did not show any significant decrease in RAAS with the comparatively lower protein levels. It is possible that the sample size of each group in the pilot study was not sufficient to identify a RAASmediating effect. It is important to note that dietary sodium and potassium differences between groups may have confounded examination of this issue. In addition, we only examined circulating RAAS biomolecules. Therefore, we cannot rule out the possibility of RAAS-related adipose and muscle-specific mechanisms related to weight loss under these conditions.
Consumption of prepared milk proteins in other studies has resulted in decreased blood pressure in moderately hypertensive subjects [28, 29, 45] . All of the subjects in our study were normotensive; therefore, no elevated RAAS levels were observed at baseline, which might have negated the ability to demonstrate a RAAS-mediating effect by whey protein during the course of the study. At the end of our study, subjects in the WP group showed a significant decrease in systolic blood pressure compared with the CD group with no significant change in RAAS activity.
Changes in circulating ACE activity did not correlate with the observed decrease in blood pressure. In contrast to our results, Harp et al [42] reported a decrease in blood pressure and ACE activity with weight loss. However, they also observed that decreases in plasma renin activity and aldosterone were more strongly associated with weight loss than was ACE activity. A trend of decreasing aldosterone concentration (P = .08) was observed in the CD and WP groups compared with the MP group. However, the similar decrease in aldosterone concentration in the CD and WP groups was not associated with similar weight loss between groups.
High-protein-reduced energy diets have been shown to maintain lean tissue while promoting decreases in fat tissue [5] . In this pilot study, there were no significant differences between groups for change in lean tissue. On average, the MP group gained lean tissue, and the WP group lost lean tissue. Because of the high availability of essential amino acids and BCAA, the observed decrease in lean tissue for the WP group was surprising. The measure of lean tissue loss in the WP group was comparable with the measure of lean tissue loss in the CD group, yet the WP group lost more weight than the CD group. Because exercise was not part of the protocol, these changes in lean tissue reflect the diet effect on lean tissue without an exercise program. If an exercise program were added to the weight loss protocol, a greater retention of lean tissue might be anticipated [46] .
Trends of decreased fat tissue were observed with the MP and WP diets compared with the CD diet. These results agree with earlier studies by Layman et al [5, 10] , who demonstrated improved body composition among those subjects assigned to a high-protein diet. Differences in body composition between treatments were most clearly observed in measures of the leg and gynoid regions. It is not clear whether or to what extent the difference in amino acid composition between treatments was related to the differences observed in fat loss and lean tissue gain between the 2 high-protein groups.
The strengths of this pilot study include the controlled feeding and parallel design, which provided opportunity to evaluate the effect of the different diets. The 3 treatments offered comparison between a standard diet and 2 variations of a high-protein diet. The comparison between high-protein diets allowed the assessment of outcome differences when different sources of protein are favored in the diet composition.
One limitation of this pilot study was small sample size. A parallel-arms design with 6 subjects in each arm provided 80% power to detect an effect size larger than 1.8 between groups, at The Labeled Affective Magnitude scale consisted of labeled terms on a 100-mm scale, with 0 mm being "Extremely Hungry," 50 mm being "Neither Hungry nor Full," and 100 mm being "Extremely Full." Data shown are means (±SEM). Week 8 difference between groups, P = .08.
the .05 level. This corresponds to a difference between groups of at least 5.6 kg in weight, 5.6 kg in total body fat mass, or 6.5 ng/L in renin. Therefore, the hypothesis of this study was rejected because these differences were not observed.
These preliminary results based on our feasibility study establish the basis for further studies regarding the effectiveness of incorporating whey protein into custom-reduced energy diets for weight loss at midlife. The trend in the WP group toward greater weight loss, greater fat loss, and reduced blood pressure compared with the other treatment groups warrants further investigation in a larger sample.
